Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ...
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0
Prnewswire Akeso Inc National Medical Products Administration Showed Clinically Meaningful Statistically Significant Benefit Patients Previously Receiving Adverse Events
Source: menafn.com